GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Cyclically Adjusted Revenue per Share

Glaukos (Glaukos) Cyclically Adjusted Revenue per Share : $6.33 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Glaukos's adjusted revenue per share for the three months ended in Mar. 2024 was $1.727. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.33 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-27), Glaukos's current stock price is $108.89. Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $6.33. Glaukos's Cyclically Adjusted PS Ratio of today is 17.20.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Glaukos was 17.45. The lowest was 9.92. And the median was 14.50.


Glaukos Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Glaukos's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cyclically Adjusted Revenue per Share Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 6.09

Glaukos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 6.10 6.09 6.33

Competitive Comparison of Glaukos's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted PS Ratio falls into.



Glaukos Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glaukos's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.727/131.7762*131.7762
=1.727

Current CPI (Mar. 2024) = 131.7762.

Glaukos Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.446 100.560 0.584
201409 0.487 100.428 0.639
201412 0.567 99.070 0.754
201503 0.494 99.621 0.653
201506 6.097 100.684 7.980
201509 0.594 100.392 0.780
201512 0.630 99.792 0.832
201603 0.646 100.470 0.847
201606 0.789 101.688 1.022
201609 0.799 101.861 1.034
201612 0.895 101.863 1.158
201703 0.951 102.862 1.218
201706 1.203 103.349 1.534
201709 1.073 104.136 1.358
201712 1.204 104.011 1.525
201803 1.157 105.290 1.448
201806 1.235 106.317 1.531
201809 1.235 106.507 1.528
201812 1.500 105.998 1.865
201903 1.492 107.251 1.833
201906 1.607 108.070 1.960
201909 1.589 108.329 1.933
201912 1.196 108.420 1.454
202003 1.264 108.902 1.530
202006 0.712 108.767 0.863
202009 1.450 109.815 1.740
202012 1.624 109.897 1.947
202103 1.487 111.754 1.753
202106 1.686 114.631 1.938
202109 1.515 115.734 1.725
202112 1.561 117.630 1.749
202203 1.367 121.301 1.485
202206 1.535 125.017 1.618
202209 1.497 125.227 1.575
202212 1.492 125.222 1.570
202303 1.543 127.348 1.597
202306 1.665 128.729 1.704
202309 1.603 129.860 1.627
202312 1.685 129.419 1.716
202403 1.727 131.776 1.727

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Glaukos  (NYSE:GKOS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glaukos's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=108.89/6.33
=17.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Glaukos was 17.45. The lowest was 9.92. And the median was 14.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Glaukos Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Glaukos's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Industry
Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022